OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00066159

Changchun High-Tech Industry Group Co Ltd

PharmaceuticalsVerified

The company maintains a relatively strong liquidity position, with a current ratio of 3.76, indicating that it has sufficient current assets to cover its current liabilities. However, its free cash flow is negative at -2546299370.0 CNY, which suggests that the company is spending more on capital expenditures than it is generating in operating cash flow. The debt-to-equity ratio is 0.1, indicating a low level of leverage and a conservative capital structure. In terms of profitability, the company's return on equity is 0.007 and return on assets is 0.0052, which are relatively low compared to industry standards. This suggests that the company is not generating significant returns for its shareholders or effectively utilizing its assets. The operating income of 391776640.0 CNY and net income of 154971450.0 CNY indicate that the company is profitable, but the margins are thin. The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed. The revenue concentration in a single geographic region may pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's revenue of 12083140490.0 CNY is derived from its pharmaceutical products, with no specific segments disclosed. The company's growth trajectory is uncertain, as there are no specific growth targets or projections provided. The capital expenditure of -2202738610.0 CNY indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive returns. The company's future revenue growth will depend on its ability to increase sales and improve operational efficiency. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital in the future. The company's conservative capital structure and low debt levels reduce the risk of financial distress, but the negative free cash flow may necessitate further financing. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and strategic direction will be closely monitored by investors and analysts. The company's ability to maintain profitability and improve cash flow will be critical to its long-term success.

30-day price · 000661-1.72 (-2.0%)
Low$84.00High$90.00Close$84.15As of15 May, 00:00 UTC
Profile
CompanyChangchun High-Tech Industry Group Co Ltd
Ticker000661.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Changchun High-Tech Industry Group Co Ltd develops and sells pharmaceutical products, primarily in China.

Classification. The company is classified in the Pharmaceuticals industry under the Healthcare economic sector with a confidence level of 0.92.

The company maintains a relatively strong liquidity position, with a current ratio of 3.76, indicating that it has sufficient current assets to cover its current liabilities. However, its free cash flow is negative at -2546299370.0 CNY, which suggests that the company is spending more on capital expenditures than it is generating in operating cash flow. The debt-to-equity ratio is 0.1, indicating a low level of leverage and a conservative capital structure. In terms of profitability, the company's return on equity is 0.007 and return on assets is 0.0052, which are relatively low compared to industry standards. This suggests that the company is not generating significant returns for its shareholders or effectively utilizing its assets. The operating income of 391776640.0 CNY and net income of 154971450.0 CNY indicate that the company is profitable, but the margins are thin. The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed. The revenue concentration in a single geographic region may pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's revenue of 12083140490.0 CNY is derived from its pharmaceutical products, with no specific segments disclosed. The company's growth trajectory is uncertain, as there are no specific growth targets or projections provided. The capital expenditure of -2202738610.0 CNY indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive returns. The company's future revenue growth will depend on its ability to increase sales and improve operational efficiency. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital in the future. The company's conservative capital structure and low debt levels reduce the risk of financial distress, but the negative free cash flow may necessitate further financing. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and strategic direction will be closely monitored by investors and analysts. The company's ability to maintain profitability and improve cash flow will be critical to its long-term success.
Key takeaways
  • The company has a strong current ratio but a negative free cash flow, indicating potential liquidity challenges.
  • The company's return on equity and return on assets are low, suggesting inefficiencies in asset utilization and profitability.
  • The company's revenue is concentrated in its domestic market, which may increase its exposure to local economic and regulatory risks.
  • The company's capital expenditures are significant, but the negative free cash flow indicates that these investments are not yet generating positive returns.
  • The company faces a medium liquidity risk and a low dilution risk, with a key flag of negative net cash after subtracting total debt.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$12.08B
Gross profit$9.78B
Operating income$391.8M
Net income$155.0M
R&D
SG&A
D&A
SBC
Operating cash flow$802.1M
CapEx-$2.20B
Free cash flow-$2.55B
Total assets$30.08B
Total liabilities$8.07B
Total equity$22.01B
Cash & equivalents
Long-term debt$2.14B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$12.08B$391.8M$155.0M-$2.55B
FY-1$13.47B$3.29B$2.58B-$696.4M
FY-2$14.57B$5.59B$4.53B$2.78B
FY-3$12.63B$4.97B$4.14B$2.07B
FY-4$10.75B$4.71B$3.76B$1.66B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$30.08B$22.01B
FY-1$31.05B$23.00B
FY-2$30.74B$22.07B
FY-3$26.03B$18.05B
FY-4$22.52B$14.57B
PeriodOCFCapExFCFSBC
FY0$802.1M-$2.20B-$2.55B
FY-1$3.10B-$2.18B-$696.4M
FY-2$5.10B-$2.10B$2.78B
FY-3$2.83B-$2.09B$2.07B
FY-4$3.33B-$2.23B$1.66B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$2.59B$353.9M$275.7M
FQ-1$2.28B-$1.00B-$1.01B
FQ-2$3.20B$251.1M$182.0M
FQ-3$3.61B$581.2M$510.2M
FQ-4$3.00B$564.5M$472.7M
FQ-5$3.08B-$82.4M-$205.8M
FQ-6$3.75B$1.21B$1.07B
FQ-7$3.46B$1.12B$861.0M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$30.77B$22.28B$2.62B
FQ-1$30.08B$22.01B
FQ-2$31.46B$23.01B$3.27B
FQ-3$31.79B$22.84B
FQ-4$31.70B$23.47B$3.90B
FQ-5$31.05B$23.00B
FQ-6$31.07B$22.98B$6.46B
FQ-7$29.98B$21.92B
PeriodOCFCapExFCFSBC
FQ0$1.10B-$435.2M
FQ-1$802.1M-$2.20B
FQ-2$721.9M-$1.38B
FQ-3$1.22B-$970.5M
FQ-4$571.1M-$590.4M
FQ-5$3.10B-$2.18B
FQ-6$3.10B-$1.59B
FQ-7$1.98B-$982.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$22.01B
Net cash-$2.14B
Current ratio3.8
Debt/Equity0.1
ROA0.5%
ROE0.7%
Cash conversion5.2%
CapEx/Revenue-18.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric000661Activity
Op margin3.2%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin1.3%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin80.9%47.8% medp25 27.6% · p75 68.9%top quartile
CapEx / revenue-18.2%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity10.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target124.96 CNY
Median price target111.34 CNY
High price target156.00 CNY
Low price target107.53 CNY
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.93 CNY
Last actual EPS0.39 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-17 03:08 UTCJob: b354f8dc